Alterome Therapeutics Appoints Leo Faoro, MD, MBA, as Chief Medical Officer [Yahoo! Finance]
Exelixis, Inc. (EXEL)
Last exelixis, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.exelixis.com/phoenix.zhtml?c=120923&p=irol-mediaresources
Company Research
Source: Yahoo! Finance
SAN DIEGO, February 02, 2026 BUSINESS WIRE Alterome Therapeutics, Inc. , a clinical-stage biopharmaceutical company pioneering the development of next-generation, small molecule targeted therapies for the treatment of cancer, today announced the appointment of Leonardo Faoro, MD, MBA, as Chief Medical Officer (CMO). Most recently, Dr. Faoro was CMO at Quanta Therapeutics, where he oversaw the clinical development of several novel KRAS inhibitors. Dr. Faoro will lead the ongoing clinical development of ALTA3263, a pan-KRAS ON/OFF inhibitor, and ALTA2618, a mutation-selective inhibitor for AKT1-driven cancers, both currently in Phase 1/1b development with initial data expected in 2026. "Alterome has made great progress in treating the most aggressive and difficult to treat cancers with two potential best-in-class programs that we advanced from inception into the clinic in less than four years," said Jung E. Choi, CEO. "With Leo's leadership and deep experience in targeted therapies—i
Show less
Read more
Impact Snapshot
Event Time:
EXEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXEL alerts
High impacting Exelixis, Inc. news events
Weekly update
A roundup of the hottest topics
EXEL
News
- Exelixis (NASDAQ:EXEL) was given a new $49.00 price target on by analysts at Morgan Stanley.MarketBeat
- Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer [Yahoo! Finance]Yahoo! Finance
- Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal CancerBusiness Wire
- Exelixis Files Zanzalintinib With FDA As Valuation Signals Upside Potential [Yahoo! Finance]Yahoo! Finance
- Assessing Exelixis (EXEL) Valuation After Recent Share Price Volatility [Yahoo! Finance]Yahoo! Finance
EXEL
Earnings
- 11/4/25 - Beat
EXEL
Sec Filings
- 1/16/26 - Form 4
- 1/16/26 - Form 4
- 1/16/26 - Form 4
- EXEL's page on the SEC website